Cg Oncology Inc
Research Cg Oncology Inc (CGON) on Bullrun: market cap USD 6.97B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCGON
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.97B
- Financial periodQ2 2026
- RevenueUSD 1.16M
- Net income-USD 79.06M
- Free cash flow-USD 46.88M
- Gross margin-239.2%
Valuation Snapshot
latest market cap is USD 6.97B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.04M | -USD 161.00M | -USD 132.48M | -15.0% | -2.08 | USD 32.49M | USD 3.00M | USD 752.60M |
| FY2024 | USD 1.14M | -USD 88.04M | -USD 78.95M | n/a | -1.41 | USD 257.07M | USD 0 | USD 733.38M |
| FY2023 | USD 204.00K | -USD 48.61M | n/a | n/a | -15.65 | USD 8.27M | USD 461.00K | -USD 123.10M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.97B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.35B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.18B | n/a | n/a | n/a |
About Cg Oncology Inc
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cg Oncology Inc's market cap?
Cg Oncology Inc's market capitalization is USD 6.97B.
What does Cg Oncology Inc do?
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.